DOCSLIB.ORG

2002 COVER PHOTO: a Schematic Diagram of the Smad Signalling System

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Bulletin The Canadian Society of Biochemistry, Molecular & Cellular Biology / La Société canadienne de biochimie, de biologie moléculaire et cellulaire 2002 www.csbmcb.ca COVER PHOTO: A schematic diagram of the Smad signalling system. (Illustration by Etienne Labbé.) Contents CSBMCB Board for 2002-2003 4 CSBMCB President’s Report 5 Incoming Members of CSBMCB Executive Board 2002-2003 6 Minutes of the 45th CSBMCB Annual General Meeting 14 CSBMCB/SC BBMC Financial Statement 20 45th Annual Meeting of the CSBMCB, Banff, Alberta 21 19th International Congress of Biochemistry & Molecular Biology 29 2003 IUBMB Toronto Congress – Background 32 Retrospective Reflections on the 11th IUB Toronto Congress 35 China and the IUB(MB)* 41 The History of Biochemistry at the University of Toronto 43 DNA 50 Years After:A Personal Perspective 48 The 2002 CSBMCB’s Merck Frosst Prize Lecture – Dr. Jeffrey Wrana 54 TGFß and the Smad Signal Transduction Pathway 55 The 2002 Jeanne Manery Fisher Memorial Lectureship Award – Dr. Mona Nemer 75 GATA-4:An Integrator of Hormonal and Growth Factor Signalling in the Heart 77 2003 Society Award Designates 82 News from Biochemistry Departments 84 CSBMCB Board for 2002-2003 PRESIDENT COUNCILLOR Dr. David W. Andrews, Tel: (905) 525-9140 Ext. 22075 Dr. Joseph R. Casey, Tel: (780) 492-7203 Department of Biochemistry, FAX: (905) 522-9033 Department of Physiology, FAX: (780)492-8915 McMaster University, E-Mail: [email protected] University of Alberta, E-Mail: [email protected] 1200 Main St.W., Edmonton, Alberta,T6G 2H7. Hamilton, Ontario, L8N 3Z5. COUNCILLOR PAST-PRESIDENT Dr. E. Bruce Waygood, Tel: (306) 966-8745 Dr. Leon W. Browder, Tel: (403) 220-6787 University Coordinator of Department of Biochemistry, Health Research, FAX: (306) 966-4737 & Molecular Biology, FAX: (403) 270-0737 209 Kirk Hall, University of University of Calgary, E-Mail: [email protected] Saskatchewan. E-Mail: [email protected] 3330 Hospital Drive, NW., 117 Science Place, Calgary, Alberta,T2N 4N1. Saskatoon, Saskatchewan, S7N 5C8. VICE-PRESIDENT COUNCILLOR Dr. John Orlowski, Tel: (514) 398-8335 Dr. Caren Helbing, Tel: Office (250) 721-6146 Department of Physiology, FAX (514) 398-7452 Department of Biochemistry McGill University, E-mail: [email protected] and Microbiology, Lab: (250) 721-7086 3655 Promenade Sir-William-Osler, Room 1112, University of Victoria, FAX: (250) 721-8855 Montreal, Quebec, H3G 1Y6. Victoria, British Columbia, V8W 3P6. E-mail: [email protected] TREASURER Dr. Fred B. Palmer, Tel: (902) 494-6436 (Office) COUNCILLOR Department of Biochemistry, FAX: (902) 494-1355 Dr. Linda Penn, Tel: (416) 946-2276 Dalhousie University, E-Mail: [email protected] Ontario Cancer Institute, FAX: (416) 946-2840 Halifax, Nova Scotia, B3H 4H7. 610 University Avenue, E-mail: [email protected] Toronto, Ontario, M5G 2M9. SECRETARY Dr. Eugene R.Tustanoff, Tel: (519) 471-1961 CHAIR, NOMINATING COMMITTEE Department of Biochemistry, FAX: (519) 661-3175 Dr. Leon Browder University of Western Ontario, E-Mail: [email protected] Committee As Above London, Ontario, N6A 5C1. BULLETIN EDITORS COUNCILLOR Dr. Frances Sharom, Tel: (519) 824-4120, Ext. 52247 Dr. Claude Lazure, Tel: (514) 987-5593 Department of Chemistry Neuropeptides Structure & and Biochemistry, FAX: (519) 766-1499 Metabolism Laboratory, FAX: (514) 987-5542 University of Guelph, E-mail: Clinical Research Institute of Guelph, Ontario, N1G 2W1. [email protected] Montreal, E-Mail: [email protected] 110 Pine Avenue West, Dr. Reinhart Reithmeier, Tel: (416) 978-2696 Montreal, Quebec, H3W 1R7. Department of Biochemistry, FAX: (416) 978-8548 University of Toronto, E-mail: [email protected] COUNCILLOR Toronto, Ontario, M5S 1A8. Dr. David Litchfield, Tel: (519) 661-4186 Department of Biochemistry, FAX: (519) 661-3175 University of Western Ontario, E-Mail: [email protected] London, Ontario, N6A 5C1. 4 CSBMCB/SCBBMC BULLETIN 2002 CSBMCB President’s Report Dr. David Andrews Do all presidents reports start off by saying it has be an event that you will been a busy, productive year? It has certainly been not want to miss. The a year of change at CSBMCB! The Society contin- organizing committee ues to promote biological sciences in Canada by headed by Joel Weiner providing exciting annual meetings and by sup- have done a fantastic porting advocacy and policy activities. The execu- job on this meeting. tive have been very active in a number of areas Frances Sharom has and I think that we are making progress towards put a lot of work into an even more energetic and vital society. our web site this year. The past year has seen another excellent meet- New features including ing at the Banff site that has become one of our an employment oppor- regular venues. Once again the meeting featured a tunities page and elec- mix of top international and national researchers. tronic membership It is always gratifying to see Canadians sharing the pages. We plan to keep podium with the best from around the world. For improving this site to me high-points included presentations of new, make it more useful and integrate it with both our controversial data that later appeared in Cell, Nat. major activities. In progress is a program to man- Cell Biol., JCB and JBC in excellent talks by Drs. age memberships that will permit us to accept Bergeron, Grinstein, Wickner and others. The membership payments over the internet and it award lectures by Drs. Wrana and Nemer were will include our own system for managing meet- also very impressive. I am very pleased to say that ing registrations in the future. we were able to sponsor a record number of stu- Thanks to the efforts of David Litchfield, we dents to attend this fabulous meeting. We all funded more student activities this year than in thank Joe Casey and his team for the work they any previous year. They included: did organizing it. University of Saskatchewan - Research Day Although not possible to organize, the weather Dalhousie - Research Symposium and the scenery were fantastic, as always. If you Cross Cancer Centre (Univ. of Alberta) - have not yet attended one of our meetings I Research Symposium strongly urge you to do so. To get a feel for it imag- York University - Research Symposium ine the best attributes of a Keystone meeting and a York University - Career Day Gorden Conference combined. The facilities in UWO - Open House/Poster Day Banff are so well suited to our meetings that we University of Calgary - Research Retreat plan to meet there again in 2005! However, our 2003 meeting will be somewhat different as it will The backbone of the society is the work done by be held jointly with the International Union of the Treasurer and the Secretary. Fred Palmer has Biochemistry July 20-24,2003. If you have not done an excellent job as treasurer for many years. already marked this meeting on your calendars - As a result the society is financially healthy, able to do it now! The meeting features symposia orga- maintain non-profit status and continues to use nized around 9 thematic areas that cover virtually the resources available in the most effective man- all of Biochemistry, Cellular and Molecular ner to support science in Canada. Our society Biology (more information can be found at: functions smoothly and things get done on time http://www.nrc.ca/confserv/iubmb2003/). It will thanks to the tremendous efforts of Gene CSBMCB/SCBBMC BULLETIN 2002 5 Tustanoff. He also provides much needed corpo- Engineering (PAGSE) as part of their annual rate memory for those of us that are ‘transients’ gala event on Parliament Hill. The topic this within the executive. year was the importance of cancer research. Advocacy or Lobbying - depending on your 7) Bruce Sells and I met with both Alan Bernstein point of view - was a major activity this year. I have and the president of CFI to promote our views listed many of our efforts in this regard below: on the payment of indirect costs to universities. 1) We put out a position paper on overhead, 8) Several of our board members (Leon Browder, many of the details of this position paper were Joe Casey, Claude Lazure, Bruce Waygood and incorporated into a report prepared and dis- myself) have been working with a group tributed to decision makers in Ottawa on our brought together by CIHR with the intention behalf by CFBS. of establishing a new grassroots organization 2) Together with CFBS we prepared a report that to advocate on behalf of health research to the was used in personal visits and distributed to general public and politicians. It is currently decision makers in Ottawa. A copy of the called the Canadian Society of Health report can be viewed at: http:/ /www Researchers, but this working name will likely .cfbs.org/CapacityforInnovation.html. evolve along with the organization. 3) We participated in the direct lobbying of MPs 9) We have been working on the development of and other decision makers in Ottawa. This more sophisticated printed materials that we lobby effort was conducted together with CFBS hope will be useful for lobbying the federal and made use of the report described above. government. For the first time we met with members of the opposition party as well as with the governing Our most important goal for next year will be to Liberals. In our meetings with members of increase our membership base. That is the only Parliament and senior bureaucrats in Ottawa way to significantly increase our effectiveness in we stressed: A) The need for more and greater advocacy, increase participation in our meetings versatility in training programs for graduate and assure continued enthusiasm for our society. and postgraduate students. B) The need for fur- I urge you to talk to your colleagues, inform them ther investments to attract and retain the best of what we are doing, encourage them to attend and brightest scientists in order to further the IUBMB meeting next summer and helps us improve productivity in both basic and health become an even more effective voice in Ottawa by research.
Recommended publications
  • Health Matters Fall 2017

    Health Matters Fall 2017

    THE OTTAWA VALLEY’S HEALTH MAGAZINE HealthMattersFREE! FALL 2017 Eating With A Happy Heart: Advice from the authors of Looneyspooons Local Canadian Experts Health Feature Facts Section: FOOD! Kids Lunch Church Suppers Hacks Around The County! Saving Silas: Meet a little boy who was The Food born with the will to live Crossword In honour of Canada’s 150th, we Canada 150 are trying to attract 150 aircraft to fly-in to the airport on one day! FLY-IN Come Join Us! Thi s goi is g n to be a very o c ay. ol d September 23rd | 10am-3pm This is a FREE event to attend. Pembroke & Area Lunch is available for purchase. AIRPORTT Plus: Ry-J’s, Aircraft Simulator, 49 Years in Aviation. and Canadian Forces aircraft on display! Easy parking in the Expo 150 field across from the airfield. Seating available at the airfield. Meet local and visiting pilots who are flying-in on this special day. 176 Len Hopkins Drive, Petawawa. Visit www.flycyta.ca/Canada150 or www.facebook.com/flycyta. Pembroke & Area AIRPORTT 49 Years in Aviation. FROM THE PUBLISHER FALL 2017 A Letter From Audrey Reader’s handwritten letter says it best about the Health Matters vision as we complete our fifth year After our last issue, I received a handwritten Ottawa Valley, even lifetime residents are letter in the mail from a woman named Audrey. unaware of! You do an excellent job of It was so compelling that I realized I could not bringing them to light, so more residents can do a better job than she did for the Publisher’s use them to make their lives better.
  • 9-Deoxy-A9,A12-13,14

    9-Deoxy-A9,A12-13,14

    Proc. Natl. Acad. Sci. USA Vol. 81, pp. 1317-1321, March 1984 Biochemistry 9-Deoxy-A9,A12-13,14-dihydroprostaglandin D2, a metabolite of prostaglandin D2 formed in human plasma (dehydration product of prostaglandin D2/serum albumin/cell growth inhibition) YOSHIHARU KIKAWA*, SHUH NARUMIYA*, MASANORI FUKUSHIMAt, HIROHISA WAKATSUKAt, AND OSAMU HAYAISHI§ *Department of Medical Chemistry, Kyoto University Faculty of Medicine, Sakyo-ku, Kyoto 606, Japan; tDepartment of Internal Medicine and Laboratory of Chemotherapy, Aichi Cancer Center, Chikusa-ku, Nagoya 464, Japan; tResearch Institute, Ono Pharmaceutical Co., Shimamoto, Mishima, Osaka 618, Japan; and §Osaka Medical College, Daigaku-cho, Takatsuki, Osaka 569, Japan Contributed by Osamu Hayaishi, November 8, 1983 ABSTRACT Incubation of prostaglandin D2 (PGD2) with from Sigma. Dimethylisopropylsilyl (Me2iPrSi) imidazole human plasma yielded a product that has been identified as 9- and methoxyamine hydrochloride were from Tokyo Kasei deoxy-9,10-didehydro-12,13-cdidehydro-13,14-dihydro-PGD2 (Tokyo). Sep-pak silica and Sep-pak C18 cartridges were (9-deoxy-_9,9'2-13,14-dihydro-PGD2). The identification was from Waters Associates. Precoated silica gel plates [G60- based on mass spectrometry, UV spectrometry, mobilities and (F254)] with concentration zones and silica gel 60 for column retention time on TLC and HPLC, and NMR. The conversion chromatography were from Merck. Sephadex LH-20 was a of PGD2 to this product was dependent on the incubation time product of Pharmacia. Solvents used in the extraction of and the amount of plasma added to a reaction mixture and was PGD2 metabolites for identification were distilled before use. abolished by prior boiling.
  • Maud Menten, a Physician and Biochemist

    Maud Menten, a Physician and Biochemist

    Maud Menten Canadian medical researcher Maud Menten (1879-1960) has been called the "grandmother of biochemistry," a "radical feminist 1920s flapper," and a "petite dynamo." Not only was she an author of Michaelis-Menten equation for enzyme kinetics (like the plot in indigo in my portrait), she invented the azo-dye coupling for alkaline phosphatase, the first example of enzyme histochemistry, still used in histochemistry imaging of tissues today (which inspired the histology background of the portrait), and she also performed the first electrophoretic separation of blood haemoglobin in 1944! Born in Port Lambton, Ontario, she studied at the University of Toronto, earning her bachelor's in 1904, and then graduated from medical school (M.B., bachelor's of medicine) in 1907. She published her first paper with Archibald Macallum, the Professor of Physiology at U of T (who went on to set up the National Research Council of Canada), on the distribution of chloride ions in nerve cells in 1906. She worked a year at the Rockefeller Institute in New York, where along with Simon Flexner, first director of the Institute, she co-authored a book on radium bromide and cancer, the first publication produced by the Institute - barely 10 years after Marie Curie had discovered radium. She completed the first of two fellowships at Western Reserve University (now Case Western Reserve University), then she earned a doctorate in medical research in 1911 at U of T. She was one of the first Canadian women to earn such an advanced medical degree. She then moved to Berlin (travelling by boat, unfazed by the recent sinking of the Titanic) to work with Leonor Michaelis.
  • Maud Leonora Menten

    Maud Leonora Menten

    Regulars Past Times A woman at the dawn of biochemistry Maud Leonora Menten Athel Cornish-Bowden Ask an average biochemist who was the first to realize that variant proteins could be detected by (Bioénergétique et Ingénierie electrophoresis and sedimentation, and had used this understanding to recognize different forms of des Protéines, CNRS and haemoglobin, the reply would probably refer to Linus Pauling and his work on sickle cell disease. Yet, Aix-Marseille Université, although this work was certainly important, that would be the wrong answer, because Maud Leonora France) and John Lagnado Menten, who sometimes seems to be remembered for one paper only, had this idea several years (Honorary Archivist, the before him, and used it to recognize the differences between foetal and adult haemoglobin1. She was Biochemical Society) unfortunate, however, in that her paper appeared in war time, and was eclipsed a few years later by a far more high-profile study2. In 2013 we celebrate two important centenaries not only of Director, and later the person who appointed Leonor the admission of women to the Biochemical Society (why Michaelis to his position there. With Flexner and James W. did it take so long?), but also of the publication of a paper Jobling, she wrote a book (the first monograph emanating by Maud Menten, who was one of the first women to leave from the Rockefeller Institute) on the effects of radium her mark in biochemistry, with a paper that is cited more bromide on tumours of animals, published in 1910 – often in the 21st Century than it was in the 20th.
  • Metabolic Tracing of NAD Precursors Using Strategically Labelled Isotopes of NMN

    Metabolic Tracing of NAD Precursors Using Strategically Labelled Isotopes of NMN

    A thesis submitted in fulfilment of the requirements for the degree of Doctor of Philosophy Metabolic tracing of NAD+ precursors using strategically labelled isotopes of NMN by Lynn-Jee Kim Supervisors Dr. Lindsay E. Wu (Primary) Prof. David A. Sinclair (Joint-Primary) Dr. Lake-Ee Quek (Co-supervisor) School of Medical Sciences Faculty of Medicine Thesis/Dissertation Sheet Surname/Family Name: Kim Given Name/s: Lynn-Jee Abbreviation for degree as give in PhD the University calendar: Faculty: Faculty of Medicine School: School of Medical Sciences + Thesis Title: Metabolic tracing of NAD precursors using strategically labelled isotopes of NMN Abstract 350 words maximum: (PLEASE TYPE) Nicotinamide adenine dinucleotide (NAD+) is an important cofactor and substrate for hundreds of cellular processes involved in redox homeostasis, DNA damage repair and the stress response. NAD+ declines with biological ageing and in age-related diseases such as diabetes and strategies to restore intracellular NAD+ levels are emerging as a promising strategy to protect against metabolic dysfunction, treat age-related conditions and promote healthspan and longevity. One of the most effective ways to increase NAD+ is through pharmacological supplementation with NAD+ precursors such as nicotinamide mononucleotide (NMN) which can be orally delivered. Long term administration of NMN in mice mitigates age-related physiological decline and alleviates the pathophysiologies associated with a high fat diet- and age-induced diabetes. Despite such efforts, there are certain aspects of NMN metabolism that are poorly understood. In this thesis, the mechanisms involved in the utilisation and transport of orally administered NMN were investigated using strategically labelled isotopes of NMN and mass spectrometry.
  • Calendar Is Brought to You By…

    Calendar Is Brought to You By…

    A Celebration of Canadian Healthcare Research Healthcare Canadian of Celebration A A Celebration of Canadian Healthcare Research Healthcare Canadian of Celebration A ea 000 0 20 ar Ye ea 00 0 2 ar Ye present . present present . present The Alumni and Friends of the Medical Research Council (MRC) Canada and Partners in Research in Partners and Canada (MRC) Council Research Medical the of Friends and Alumni The The Alumni and Friends of the Medical Research Council (MRC) Canada and Partners in Research in Partners and Canada (MRC) Council Research Medical the of Friends and Alumni The The Association of Canadian Medical Colleges, The Association of Canadian Teaching Hospitals, Teaching Canadian of Association The Colleges, Medical Canadian of Association The The Association of Canadian Medical Colleges, The Association of Canadian Teaching Hospitals, Teaching Canadian of Association The Colleges, Medical Canadian of Association The For further information please contact: The Dean of Medicine at any of Canada’s 16 medical schools (see list on inside front cover) and/or the Vice-President, Research at any of Canada’s 34 teaching hospitals (see list on inside front cover). • Dr. A. Angel, President • Alumni and Friends of MRC Canada e-mail address: [email protected] • Phone: (204) 787-3381 • Ron Calhoun, Executive Director • Partners in Research e-mail address: [email protected] • Phone: (519) 433-7866 Produced by: Linda Bartz, Health Research Awareness Week Project Director, Vancouver Hospital MPA Communication Design Inc.: Elizabeth Phillips, Creative Director • Spencer MacGillivray, Production Manager Forwords Communication Inc.: Jennifer Wah, ABC, Editorial Director A.K.A. Rhino Prepress & Print PS French Translation Services: Patrice Schmidt, French Translation Manager Photographs used in this publication were derived from the private collections of various medical researchers across Canada, The Canadian Medical Hall of Fame (London, Ontario), and First Light Photography (BC and Ontario).
  • Sunnybrook Department of Medicine Annual Report 2012

    Sunnybrook Department of Medicine Annual Report 2012

    DEPARTMENT OF MEDICINE ANNUAL REPORT July 1, 2012 – June 30, 2013 Sunnybrook DEPARTMENT OF MEDICINE DEPARTMENT OF MEDICINE ANNUAL REPORT July 1, 2012 – June 30, 2013 Table of Contents MESSAGE FROM THE PHYSICIAN-IN-CHIEF 3 APPENDIXES 37 EXECUTIVE SUMMARY 4 APPENDIX I: LIST OF FACULTY 38 ABOUT US: 4 APPENDIX II: SUMMARY ACTIVITY REPORTS 40 MEMBERS OF THE EXECUTIVE COMMITTEE 6 OVERALL DEPARTMENTAL SUMMARY 41 COMMITTEE REPORTS 7 DIVISION OF CARDIOLOGY 42 DIVISION OF DERMATOLOGY 55 FACULTY 9 DIVISION OF ENDOCRINOLOGY FULL-TIME FACULTY BY DIVISION 9 AND METABOLISM 58 FULL-TIME FACULTY BY UNIVERSITY RANK 10 DIVISION OF GASTROENTEROLOGY 62 FULL-TIME FACULTY BY JOB DESCRIPTION 10 DIVISION OF GENERAL INTERNAL MEDICINE 66 NEW APPOINTMENTS 11 DIVISION OF GERIATRIC MEDICINE 77 PROMOTIONS 11 DIVISION OF INFECTIOUS DISEASES 79 2013 DEPARTMENT OF MEDICINE AWARD RECIPIENTS 12 DIVISION OF MEDICAL ONCOLOGY AND EXTERNAL LEADERSHIP POSITIONS 12 HEMATOLOGY 88 FACULTY WELL-BEING COMMITTEE 13 DIVISION OF NEPHROLOGY 110 STRATEGIC PLAN 14 DIVISION OF NEUROLOGY 116 SHORT-TERM GOALS 2013-2014 15 DIVISION OF PHYSIATRY, PHYSICAL MEDICINE AND REHABILITATION 131 DIVISION REPORTS 16 DIVISION OF RESPIROLOGY 132 CARDIOLOGY 17 DIVISION OF RHEUMATOLOGY 136 CLINICAL PHARMACOLOGY & TOXICOLOGY 19 MISSION, VISION & VALUES STATEMENTS 139 DERMATOLOGY 20 MISSION 139 ENDOCRINOLOGY 21 VISION 139 GASTROENTEROLOGY 23 VALUES 139 GENERAL INTERNAL MEDICINE 25 ORGANIZATION CHART 139 GERIATRIC MEDICINE 26 INFECTIOUS DISEASES 28 MEDICAL ONCOLOGY & CLINICAL HEMATOLOGY 29 NEPHROLOGY 30 NEUROLOGY 31 OBSTETRICAL MEDICINE 32 REHABILITATION MEDICINE 33 RESPIROLOGY 35 RHEUMATOLOGY 36 2 MESSAGE FROM THE PHYSICIAN-IN-CHIEF I am pleased to share this annual report for the 2012-13 academic year with you.
  • Suppression of Poly(ADP-Ribose)

    Suppression of Poly(ADP-Ribose)

    Proc. Nati. Acad. Sci. USA Vol. 81, pp. 7132-7136, November 1984 Cell Biology Induction of murine teratocarcinoma cell differentiation by suppression of poly(ADP-ribose) synthesis (NADW/retinoic acid/3-aminobenzamide/immunofluorescence) YASUHIRO OHASHI*t, KUNIHIRO UEDA*t, OSAMU HAYAISHI*§, KouICHI IKAI¶, AND OTSURA NIWAII Departments of *Medical Chemistry, ¶Dermatology, and "Experimental Radiology, Kyoto University Faculty of Medicine, Yoshida, Sakyo-ku, Kyoto 606, Japan Contributed by Osamu Hayaishi, July 27, 1984 ABSTRACT Poly(ADP-ribose) synthesizing activity in present study, we report a marked decrease in nuclear po- mouse teratocarcinoma EC-Al cells decreased markedly dur- ly(ADP-ribose) synthesizing activity at a very early stage of ing differentiation induced by retinoic acid; the activities as- differentiation of teratocarcinoma cells induced by retinoic sayed in permeabilized cells decreased to 25% and 10% of the acid. Furthermore, we present evidence suggesting that ex- activity of control (uninduced cells) 2 and 3 days, respectively, ogenously added inhibitors of poly(ADP-ribose) synthetase after the addition of 0.1 ,uM retinoic acid to the culture medi- can induce the differentiation of these cells. um. This change preceded changes in morphology and DNA synthesis, which became prominent after 4 days. The decrease MATERIALS AND METHODS in poly(ADP-ribose) synthesizing activity appeared to be caused by a diminution of the synthetase protein and not by a Chemicals. [adenine-U-14C]NAD+ (266 Ci/mol; 1 Ci = 37 decrease in its catalytic activity, because the full activity dis- GBq) and [methyl-3H]dTTP (30 Ci/mmol) were purchased closed by DNase I treatment decreased in parallel, albeit at from Amersham.
  • Effects of 5-Hydroxykynurenamine, a New Serotonin Metabolite

    Effects of 5-Hydroxykynurenamine, a New Serotonin Metabolite

    Proc. Nat. Acad. Sci. USA Vol. 71, No. 1, pp. 122-124, January 1974 Effects of 5-Hydroxykynurenamine, a New Serotonin Metabolite, on Isolated Dog Basilar Arteries (serotonin/amine/antagonist/artery) NOBORU TODA*, TAKASHI TOKUYAMAt, SIRO SENOHt, FUSAO HIRATA§, AND OSAMU HAYAISHI§ * Department of Pharmacology, and § Department of Medical Chemistry, Kyoto University Faculty of Medicine, Kyoto; t Department of Chemistry, Osaka City University Faculty of Science, Osaka; and $ Central Research Institute, Suntory Ltd., Osaka, Japan Contributed by Osamu Hayaishi, September 10, 1973 ABSTRACT Serotonin and 5-hydroxykynurenamine HK and serotonin were added directly to the bathing me- caused dose-related contractions in the spiral strips of dium in cumulative concentrations at the time when the dose- dog basilar arteries. The potency of 5-hydroxykynuren- amine was approximately 1/100 that of serotonin, the response curve was obtained. former frequently causing a transient relaxation preceding the contraction. The contractile responses to 5-hydroxy- RESULTS kynurenamine and serotonin were attenuated by methy- Serotonin in concentrations ranging from 10-9 to 10-5 M sergi(le. Treatment with 5-hydroxykynurenamine inhib- caused a dose-related increase in the tension of basilar arterial ited the response to serotonin, and this inhibitory effect was not completely reversed by removal of 5-hydroxy- strips (Fig. 1A). Contractile responses to serotonin were kvnurenamine from the bathing medium. The contractile reproducible five times when preparations were repeatedly response to K+ was only slightly attenuated by high con- washed and equilibrated in normal solutions for 40-60 min. centrations of 5-hydroxykynurenamine. It appears that 5-HEK (5 X 10-' to 5 X 10-5 M) caused slowly developing 5-hydroxykynurenamine and serotonin share receptors in contractions in a dose-dependent manner (Fig.
  • By the Numbers Excellence, Innovation, Leadership: Research at the University of Toronto a Powerful Partnership

    By the Numbers Excellence, Innovation, Leadership: Research at the University of Toronto a Powerful Partnership

    BY THE NUMBERS EXCELLENCE, INNOVATION, LEADERSHIP: RESEARCH AT THE UNIVERSITY OF TORONTO A POWERFUL PARTNERSHIP The combination of U of T and the 10 partner hospitals affiliated with the university creates one of the world’s largest and most innovative health research forces. More than 1,900 researchers and over 4,000 graduate students and postdoctoral fellows pursue the next vital steps in every area of health research imaginable. UNIVERSITY OF TORONTO Sunnybrook Health St. Michaelʼs Sciences Centre Hospital Womenʼs College Bloorview Kids Hospital Rehab A POWERFUL PARTNERSHIP Baycrest Mount Sinai Hospital The Hospital University Health for Sick Children Network* Centre for Toronto Addiction and Rehabilitation Mental Health Institute *Composed of Toronto General, Toronto Western and Princess Margaret Hospitals 1 UNIVERSITY OF TORONTO FACULTY EXCELLENCE U of T researchers consistently win more prestigious awards than any other Canadian university. See the end of this booklet for a detailed list of awards and honours received by our faculty in the last three years. Faculty Honours (1980-2009) University of Toronto compared to awards held at other Canadian universities International American Academy of Arts & Sciences* Gairdner International Award Guggenheim Fellows National Academies** Royal Society Fellows Sloan Research Fellows American Association for the Advancement of Science* ISI Highly-Cited Researchers*** 0 20 40 60 801 00 Percentage National Steacie Prize Molson Prize Federal Granting Councilsʼ Highest Awards**** Killam Prize Steacie
  • IUBMB Newsletter Issue 2.Pdf

    IUBMB Newsletter Issue 2.Pdf

    IUBMB NEWS Issue 2 October 2016 President’s Message IUBMB aims to promote research and education in In This Issue Biochemistry and Molecular Biology. In this regard, over the President’s Message years we have channelled great efforts into the research aspects of our science. We now consider it timely to turn our Report on the 16th IUBMB attention to educational initiatives. Conference / Young To address this aim and in collaboration with FEBS, we are organising a conference on Education in Biochemistry and Molecular Biology, to be held in Scientists’ Program Rehovot (Israel) in September 2017. The conference seeks to provide a think-tank Tang Prize Foundation setting in which to draw up ideas to improve the current approach to teaching these subjects, and to generate a series of recommendations to be shared with Awardees / IUBMB Travel the educational community. In this regard, this conference will serve to propel the Fellowships changes that are required to bring education in biochemistry and molecular biology st at all levels into the 21 century. Another Way to Think About Another important aspect of education is to provide young scientists from Disease by Gregory Petsko developing countries the opportunity to attend international congresses and meetings. IUBMB is firmly committed to this endeavour and devotes significant Retrospective — financial resources to this end. Given that the number of applications from African countries is very low, I wish to encourage our young African colleagues to apply Osamu Hayaishi and benefit from IUBMB travel awards and Wood-Whelan fellowships. An Appreciation — IUBMB is also launching a new activity, namely Focused Meetings.
  • Printable List of Laureates

    Printable List of Laureates

    Laureates of the Canadian Medical Hall of Fame A E Maude Abbott MD* (1994) Connie J. Eaves PhD (2019) Albert Aguayo MD(2011) John Evans MD* (2000) Oswald Avery MD (2004) F B Ray Farquharson MD* (1998) Elizabeth Bagshaw MD* (2007) Hon. Sylvia Fedoruk MA* (2009) Sir Frederick Banting MD* (1994) William Feindel MD PhD* (2003) Henry Barnett MD* (1995) B. Brett Finlay PhD (2018) Murray Barr MD* (1998) C. Miller Fisher MD* (1998) Charles Beer PhD* (1997) James FitzGerald MD PhD* (2004) Bernard Belleau PhD* (2000) Claude Fortier MD* (1998) Philip B. Berger MD (2018) Terry Fox* (2012) Michel G. Bergeron MD (2017) Armand Frappier MD* (2012) Alan Bernstein PhD (2015) Clarke Fraser MD PhD* (2012) Charles H. Best MD PhD* (1994) Henry Friesen MD (2001) Norman Bethune MD* (1998) John Bienenstock MD (2011) G Wilfred G. Bigelow MD* (1997) William Gallie MD* (2001) Michael Bliss PhD* (2016) Jacques Genest MD* (1994) Roberta Bondar MD PhD (1998) Gustave Gingras MD* (1998) John Bradley MD* (2001) Phil Gold MD PhD (2010) Henri Breault MD* (1997) Richard G. Goldbloom MD (2017) G. Malcolm Brown PhD* (2000) Jean Gray MD (2020) John Symonds Lyon Browne MD PhD* (1994) Wilfred Grenfell MD* (1997) Alan Burton PhD* (2010) Gordon Guyatt MD (2016) C H G. Brock Chisholm MD (2019) Vladimir Hachinski MD (2018) Harvey Max Chochnov, MD PhD (2020) Antoine Hakim MD PhD (2013) Bruce Chown MD* (1995) Justice Emmett Hall* (2017) Michel Chrétien MD (2017) Judith G. Hall MD (2015) William A. Cochrane MD* (2010) Michael R. Hayden MD PhD (2017) May Cohen MD (2016) Donald O.